Sabra Health Care REIT, Inc. to Participate in BofA’s 2021 Global Real Estate Conference

Sabra Health Care REIT, Inc. to Participate in BofA’s 2021 Global Real Estate Conference

IRVINE, Calif.–(BUSINESS WIRE)–
Sabra Health Care REIT, Inc. (Nasdaq: SBRA) announced today that Rick Matros, the company’s Chair and Chief Executive Officer, Harold Andrews, the company’s Chief Financial Officer, Talya Nevo-Hacohen, the company’s Chief Investment Officer, and Michael Costa, the company’s Executive Vice President of Finance and Chief Accounting Officer, will participate virtually in BofA’s 2021 Global Real Estate Conference on September 23, 2021.

About Sabra

Sabra Health Care REIT, Inc., a Maryland corporation, operates as a self-administered, self-managed real estate investment trust (a “REIT”) that, through its subsidiaries, owns and invests in real estate serving the healthcare industry throughout the United States and Canada.

Investor & Media Inquiries: 1-888-393-8248 or [email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Construction & Property Health REIT Other Health

MEDIA:

Logo
Logo

Altice USA Announces Leadership Changes

Altice USA Announces Leadership Changes

NEW YORK–(BUSINESS WIRE)–
Altice USA (NYSE: ATUS) today announces that Hakim Boubazine, Chief Operating Officer and President of Telecommunications, has resigned from the Company. Altice USA Chief Executive Officer Dexter Goei will assume direct responsibilities for the Telecommunications division, effective immediately. Mr. Boubazine will serve as Senior Advisor to the CEO until December 31, 2021.

Altice USA notes that it has an experienced senior Telecommunications management team in place who will now report directly to Mr. Goei. This new management structure is designed to accelerate the Company’s growth initiatives and enhance the day-to-day management decision-making processes.

Mr. Goei commented: “It has been a pleasure to work with Hakim, and I want to thank him for the critical role he has played over the last six years at Altice USA. We appreciate the time he will serve as a senior advisor and wish him much success in his future endeavors.”

Added Mr. Boubazine: “Working at Altice USA has been one of the most rewarding experiences in my career, and I could not be prouder of what we accomplished together. I am grateful for the opportunity to serve such an innovative, entrepreneurial, and inclusive organization, and I want to thank Patrick Drahi and Dexter for their trust over the years. I have the utmost confidence in the entire Altice USA management team for achieving future success.”

About Altice USA

Altice USA is one of the largest broadband communications and video services providers in the United States, delivering broadband, video, mobile, proprietary content and advertising services to more than 5 million residential and business customers across 21 states through its Optimum and Suddenlink brands. The company operates a4, an advanced advertising and data business, which provides audience-based, multiscreen advertising solutions to local, regional and national businesses and advertising clients. Altice USA also offers hyper-local, national, international and business news through its News 12, Cheddar and i24NEWS networks.

Investor Relations

Nick Brown: +1 917 589 9983 /
[email protected]

Media

Lisa Anselmo: +1 516 279 9461 /
[email protected]

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Telecommunications Networks Internet Audio/Video Technology VoIP Mobile/Wireless Other Technology

MEDIA:

OrthoPediatrics Announces Entry into a Distribution Agreement with SeaSpine to Exclusively Distribute the 7D Surgical FLASH Navigation Platform for Pediatric Applications

Enables OrthoPediatrics to Further Address Full Patient Continuum of Care for Pediatric Orthopedic Surgeons with Market-Leading, Radiation-Free Navigation Technology

WARSAW, Ind., Sept. 09, 2021 (GLOBE NEWSWIRE) — OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced they have entered into a distribution agreement with SeaSpine® Orthopedics Corporation, a wholly-owned subsidiary of SeaSpine Holdings Corporation (Nasdaq: SPNE), to exclusively distribute the 7D Surgical FLASH™ Navigation platform for pediatric applications. The 5-year exclusive agreement enables OrthoPediatrics to further address the full patient continuum of care for pediatric orthopedic surgeons with market-leading, radiation-free navigation technology.

“We are excited to enter into this relationship with SeaSpine enabling us to provide our pediatric orthopedic customers with direct access to the best-in-class 7D navigation technology,” said Greg Odle, Executive Vice President of OrthoPediatrics. “OrthoPediatrics acknowledges the importance of providing complete procedural solutions and innovations to improve surgical workflow and patient safety.”

The 7D FLASH Navigation System is the only approved image guidance system that utilizes a novel and proprietary camera-based technology and machine-vision algorithms. The system uses only visible light, reducing radiation exposure by eliminating intra-operative CT (computed tomography) and fluoroscopy for purposes of registration, both of which commonly are used with other technologies. This results in a registration workflow that takes just seconds and allows surgeons to control the system within the sterile field.

“Our commitment to innovation demonstrated by this partnership combined with the recent extension of our distribution agreement with Mighty Oak Medical to sell its Firefly technology is part of our strategy to offer a unique suite of enabling technologies,” said Fred Hite, OrthoPediatrics’ COO/CFO. “Combining these navigation solutions with the most comprehensive pediatric-focused offering of orthopedic product solutions globally, we believe this agreement will also allow us to provide a capital-efficient means of acquiring the 7D FLASH navigation system for our customers, and for the betterment of children everywhere.”

“This transaction enhances our team’s ability to do what we love – accelerate innovation and pioneer ground-breaking technologies,” said Beau Standish, SeaSpine’s President, Enabling Technologies. “Leveraging our expertise in machine-vision, intelligent software and advanced optics, with OrthoPediatrics’ comprehensive channel to market, provides a clear pathway to expand our reach and deliver tremendous value to the pediatric patient population.”

About OrthoPediatrics Corp.

Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 36 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and 45 countries outside the United States. For more information, please visit www.orthopediatrics.com.

About SeaSpine
SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions, as well as a market leading surgical navigation system, to meet the varying combinations of products and enabling technologies that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in orthobiologic sciences, as well as spinal implants, software and advanced optics product development, allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide through a committed network of increasingly exclusive distribution partners.

Investor Contacts

Gilmartin Group

For OrthoPediatrics:
Matt Bacso, CFA
[email protected]

For SeaSpine:
Leigh Salvo
[email protected] or [email protected]



  Shipments per Workday Weight per Shipment Tonnage per Workday Revenue per Hundredweight(a) Revenue per Shipment(a)
July (3.9)% (1.9)% (5.7)% 19.4% 17.1%
August (6.4)% (2.2)% (8.5)% 22.5% 19.9%
QTD (5.2)% (2.0)% (7.1)% 20.9% 18.5%
           
(a) Includes fuel surcharge

“We continue executing our yield strategy to ensure the optimum level of freight is flowing through the network,” said Darren Hawkins, Chief Executive Officer. “Our plan is to grow the business and we are confident that our transformation to One Yellow positions us for long-term tonnage growth. Extraordinarily tight LTL capacity with ongoing high demand matched by limits in the U.S. labor pool reinforces our near- term strategy of focusing on yield at this point in the freight transportation cycle.”


Cautionary Note on Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements include those preceded by, followed by or characterized by words such as “will,” “expect,” “intend,” “anticipate,” “believe,” “could,” “should,” “may,” “project,” “forecast,” “propose,” “plan,” “designed,” “estimate,” “enable,” and similar expressions which speak only as of the date the statement was made. Forward-looking statements are inherently uncertain, are based upon current beliefs, assumptions and expectations of Company management and current market conditions, and are subject to significant business, economic, competitive, regulatory and other risks, uncertainties and contingencies, known and unknown, many of which are beyond our control. Readers are cautioned not to place undue reliance on any forward-looking statements. Our future financial condition and results could differ materially from those predicted in such forward-looking statements because of a number of business, financial and liquidity, and common stock related factors, including (without limitation) the risk of labor disruptions or stoppages, if our relationship with our employees and unions were to deteriorate; general economic factors, including (without limitation) impacts of COVID-19 and customer demand in the retail and manufacturing sectors; the widespread outbreak of an illness or any other communicable disease, including the effects of pandemics comparable to COVID-19, or any other public health crisis, as well as regulatory measures implemented in response to such events; interruptions to our computer and information technology systems and sophisticated cyber-attacks; business risks and increasing costs associated with the transportation industry, including increasing equipment, operational and technology costs and disruption from natural disasters, and impediments to our operations and business resulting from anti-terrorism measures; our ability to attract and retain qualified drivers and increasing costs of driver compensation; competition and competitive pressure on pricing; changes in pension expense and funding obligations, subject to interest rate volatility; increasing costs relating to our self-insurance claims expenses; our ability to comply and the cost of compliance with, or liability resulting from violation of, federal, state, local and foreign laws and regulations, including (without limitation) labor laws and laws and regulations regarding the environment and climate change initiatives; the impact of claims and litigation expense to which we are or may become exposed; that we may not realize the expected benefits and costs savings from our performance and operational improvement initiatives; a significant privacy breach or IT system disruption; our dependence on key employees; our ability to finance the maintenance, acquisition and replacement of revenue equipment and other necessary capital expenditures; seasonality and the impact of weather; shortages of fuel and changes in the cost of fuel or the index upon which we base our fuel surcharge and the effectiveness of our fuel surcharge program in protecting us against fuel price volatility; risks of operating in foreign countries; our failure to comply with the covenants in the documents governing our existing and future indebtedness; our ability to generate sufficient liquidity to satisfy our indebtedness and cash interest payment obligations, lease obligations and pension funding obligations; fluctuations in the price of our common stock; dilution from future issuances of our common stock; we are not permitted to pay dividends on our common stock in the foreseeable future; that we have the ability to issue preferred stock that may adversely affect the rights of holders of our common stock; and other risks and contingencies, including (without limitation) the risk factors that are included in our reports filed with the SEC, including those described under “Risk Factors” in our annual report on Form 10-K and quarterly reports on Form 10-Q.

About Yellow Corporation

Yellow Corporation has one of the largest, most comprehensive logistics and less-than-truckload (LTL) networks in North America with local, regional, national, and international capabilities. Through its teams of experienced service professionals, Yellow Corporation offers industry-leading expertise in flexible supply chain solutions, ensuring customers can ship industrial, commercial, and retail goods with confidence. Yellow Corporation, headquartered in Overland Park, Kan., is the holding company for a portfolio of LTL brands including Holland, New Penn, Reddaway, and YRC Freight, as well as the logistics company HNRY Logistics.

Please visit our website at www.myyellow.com for more information.

Investor Contact: Tony Carreño
913-696-6108
[email protected]
   
Media Contacts: Mike Kelley
913-696-6121
[email protected]

Heather Nauert
[email protected]



DaVita Announces Dr. Gregory Moore to Join its Board of Directors

PR Newswire

DENVER, Sept. 9, 2021 /PRNewswire/ — DaVita Inc. announced today that its Board of Directors appointed a new independent director, Gregory Moore, M.D., Ph.D., to join the Board, effective Sept. 9, 2021.

Dr. Moore brings nearly 20 years of health care experience to the Board. In his current role as corporate vice president for Microsoft Health & Life Sciences, Dr. Moore is Microsoft’s global health and life sciences leader, responsible for leading research and development collaborations, strategy, AI and machine learning engineering teams and cloud and data product development teams to positively transform health. Prior to Microsoft, Dr. Moore served as vice president at Google leading Google Cloud Health and Life Sciences globally. Dr. Moore is an industry thought leader, driving innovation to enable access to care and digital transformation toward a more transparent, interoperable and AI-driven foundation for health care delivery.

“We’re thrilled to add Greg’s focus on technology-driven health care experiences to our Board to help us accelerate digital transformation in kidney care,” said Javier Rodriguez, CEO of DaVita Inc. “He strengthens our capabilities to develop new solutions that will move us closer to the seamless care environment we’re building for our patients in the future.”

Dr. Moore is a practicing physician and experienced educator. He is board certified in Diagnostic Radiology, Neuroradiology and Clinical Informatics. Prior to his leadership roles at Microsoft and Google, Dr. Moore served as the chief emerging technology and informatics officer at Geisinger Health System, where he was also Director of the Institute of Advanced Application. He has held prior academic and clinical appointments at Stanford University School of Medicine, Penn State University College of Medicine and Wayne State University School of Medicine.

“DaVita’s deep commitment to patients and driving true transformation in health care led me to this role,” said Dr. Moore. “I’m excited to share my perspective on how technology-driven tools can enable access to personalized care and help facilitate better health outcomes.”

Dr. Moore will serve on the Nominating and Governance Committee and the Compliance and Quality Committee of DaVita’s Board. He also serves on the Hill-Rom Holdings Board of Directors.

“Greg brings a proven track record of innovation and passion for transforming health care experiences, making him a great addition to the team,” said Pam Arway, independent chair of the DaVita Inc. Board of Directors.

With the addition of Dr. Moore, the DaVita Board is composed of nine highly qualified directors, with 33 percent racial/ethnic and 44 percent gender diversity. To learn more about DaVita and its Board of Directors, visit DaVita.com/About.

About DaVita Inc.
DaVita (NYSE: DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. The company is one of the largest providers of kidney care services in the U.S. and has been a leader in clinical quality and innovation for more than 20 years. DaVita cares for patients at every stage and setting along their kidney health journey—from slowing the progression of kidney disease to helping to support transplantation, from acute hospital care to dialysis at home. As of June 30, 2021, DaVita served 204,300 patients at 2,828 outpatient dialysis centers in the United States. The company also operated 331 outpatient dialysis centers in ten countries worldwide. DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care industry to adopt an equitable and high-quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About.

Investor Contact Information

Jim Gustafson

[email protected]

310-536-2585

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/davita-announces-dr-gregory-moore-to-join-its-board-of-directors-301372915.html

SOURCE DaVita Inc.

Dynavax to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

PR Newswire

EMERYVILLE, Calif., Sept. 9, 2021 /PRNewswire/ — Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, today announced that Ryan Spencer, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021.

The on demand presentation will be available, beginning Monday, September 13, 2021 at 7:00 a.m. E.T. and may be accessed through the “Events & Presentations” page on the “Investors” section of the Company’s website at http://investors.dynavax.com/events-presentations.

About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company’s first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and Europe for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.

Contacts:

Nicole Arndt

[email protected] 
510-665-7264

Derek Cole, President
Investor Relations Advisory Solutions
[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-present-at-the-hc-wainwright-23rd-annual-global-investment-conference-301372861.html

SOURCE Dynavax Technologies

Sumo Logic Announces Second Quarter Fiscal 2022 Financial Results

Second quarter revenue grew 19% year-over-year to $58.8 million

Named a Visionary in the 2021 Gartner Magic Quadrant for Security Information and Event Management (SIEM)

REDWOOD CITY, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) —  Sumo Logic (Nasdaq: SUMO), a pioneer of continuous intelligence, today announced financial results for the second quarter of its fiscal 2022, ended July 31, 2021.

“This quarter we saw continued momentum in our business as new and current customers adopt our Continuous Intelligence platform for a broad range of Observability and Security use cases,” said Ramin Sayar, president and CEO of Sumo Logic. “We will continue to invest in platform expansion and expanded routes to market to position us to capture the significant opportunity created by digital transformation and cloud migration.”

Second Quarter Fiscal 2022 Financial Highlights

  • Revenue was $58.8 million, an increase of 19% year-over-year
  • Revenue, excluding our largest revenue customer, was $54.9 million, an increase of 21% year-over-year
  • GAAP gross margin was 66%; non-GAAP gross margin was 72%
  • GAAP operating loss was $32.9 million; GAAP operating margin was (56)%
  • Non-GAAP operating loss was $12.4 million; non-GAAP operating margin was (21)%
  • GAAP net loss was $32.0 million or $0.30 per share
  • Non-GAAP net loss was $11.5 million or $0.11 per share
  • Net cash used in operating activities was $4.5 million; free cash flow was $(5.6) million
  • Cash and cash equivalents and marketable securities were $371.7 million as of July 31, 2021

Recent Highlights

  • Recognized as a Visionary in Gartner’s 2021 Magic Quadrant for SIEM, which positions vendors according to their ability to execute and the completeness of their vision.
  • Announced the general availability of Sumo Logic Cloud SOAR to help enterprises modernize the security operations center (SOC). Sumo Logic Cloud SOAR improves SOC productivity, increases visibility, enhances incident response, and helps security professionals make insightful decisions.
  • Closed our acquisition of Sensu, Inc. (Sensu), a leader in open source monitoring. The addition of Sensu accelerates Sumo Logic’s observability strategy by providing customers with an affordable and scalable end-to-end solution for infrastructure and application monitoring.
  • Announced new capabilities as part of its Observability solution, including Real User Monitoring and Span Analytics, designed to help DevOps and site reliability engineer teams identify and resolve customer-impacting issues faster, reduce application downtime, and optimize application performance.
  • Announced a partnership with SYNNEX, a leading distributor, to deliver a customizable cloud-native security practice leveraging Sumo Logic’s Practice Builder program to enable customers to get real-time analytics and security insights into applications and infrastructure across their on-premises and cloud environments.
  • Announced the availability of Sumo Logic’s Continuous Intelligence Platform™ on Red Hat Marketplace, operated by IBM, allowing companies to purchase its cloud-native security and observability solutions that are running on the Red Hat OpenShift platform.
  • Announced the appointment of Margaret Francis to our Board of Directors. Francis brings deep experience leading product and engineering strategy for high growth software companies across SaaS, PaaS, data and developer technologies. Her expertise will help guide Sumo Logic’s product and engineering strategy to further serve the DevSecOps market opportunity.
  • Sumo Logic will host its 5th annual user conference, Illuminate, from September 28-29, 2021, a free virtual event. Illuminate is a premier global education user conference that brings together our customers with thought leaders in IT operations, development and operations, and security.

Financial Outlook

For the third quarter of fiscal 2022, Sumo Logic expects:

  • Total revenue between $60.3 million and $61.3 million, representing 16% to 18% growth year over year
  • Revenue, excluding our largest revenue customer, between $56.1 million and $57.1 million, representing 17% to 19% growth year over year
  • Non-GAAP operating loss of $15.5 million to $15.0 million; non-GAAP operating margin of (26)% to (24)%
  • Non-GAAP net loss per share of $0.14 on approximately 110.2 million weighted average shares outstanding

For the full fiscal year 2022, Sumo Logic expects:

  • Total revenue between $236.8 million and $238.8 million, representing 17% to 18% growth year over year
  • Revenue, excluding our largest revenue customer, between $221.2 million and $223.2 million, representing 18% to 19% growth year over year
  • Non-GAAP operating loss of $55.5 million to $54.5 million; non-GAAP operating margin of (23)%
  • Non-GAAP net loss per share of $0.52 to $0.51 on approximately 108.3 million weighted average shares outstanding

These statements are forward-looking and actual results may differ materially. Please refer to the Forward-Looking Statements safe harbor below for information on the factors that could cause our actual results to differ materially from these forward-looking statements.

Guidance for non-GAAP financial measures excludes stock-based compensation expense and related employer payroll taxes, amortization of acquired intangible assets, and acquisition-related expenses. We have not provided the most directly comparable GAAP measures because certain items are out of our control or cannot be reasonably predicted. Accordingly, a reconciliation for forward-looking non-GAAP operating loss and non-GAAP net loss per share is not available without unreasonable effort. Refer to Non-GAAP Financial Measures below.

Conference Call Details

The company will host a conference call and live webcast on Thursday, September 9, 2021, at 1:30 p.m. Pacific time (4:30 p.m. Eastern time). The news release with the financial results will be accessible on Sumo Logic’s investor relations website at investor.sumologic.com prior to the conference call. To access the conference call, dial (877) 407-0784 from the United States or (201) 689-8560 internationally and reference the company name and conference title. Following the completion of the call, a replay will be available for approximately two weeks. The replay can be accessed by dialing (844) 512-2921 from the United States or (412) 317-6671 internationally and using the recording passcode 13722497. A live webcast and replay of the conference call can also be accessed from the Sumo Logic Investor Relations website at investor.sumologic.com.

Supplemental Financial and Other Information

Supplemental financial and other information can be accessed through Sumo Logic’s investor relations website at investor.sumologic.com. Sumo Logic uses the investor relations section on its website as the means of complying with its disclosure obligations under Regulation FD. Accordingly, we recommend that investors should monitor Sumo Logic’s investor relations website in addition to following Sumo Logic’s press releases, SEC filings and social media.

Non-GAAP Financial Measures

In addition to our financial information presented in accordance with GAAP, we believe the following non-GAAP financial measures are useful in evaluating our operating performance. We use the following non-GAAP financial measures, collectively, to evaluate our ongoing operations and for internal planning and forecasting purposes, including the preparation of our annual operating budget and quarterly forecasts, to evaluate the effectiveness of our business strategies, and to communicate with our board of directors concerning our financial performance. We believe that non-GAAP financial measures, when taken together with the corresponding GAAP financial measures, may be helpful to investors because they provide consistency and comparability with past financial performance and meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations, or outlook. The non-GAAP financial measures are presented for supplemental informational purposes only, have limitations as analytical tools, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP and may be different from similarly-titled non-GAAP financial measures used by other companies. In addition, other companies, including companies in our industry, may calculate similarly-titled non-GAAP financial measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business, which it includes in press releases announcing quarterly financial results, including this press release.


Non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating expenses, non-GAAP loss from operations, non-GAAP operating margin, non-GAAP net loss and non-GAAP net loss per share:
We define these non-GAAP financial measures as their respective GAAP measures, excluding expenses related to stock-based compensation expense and related employer taxes on equity, amortization of acquired intangibles, and acquisition-related expenses. We use these non-GAAP financial measures as part of our overall assessment of our performance, including the preparation of our annual operating budget and quarterly forecasts, to evaluate the effectiveness of our business strategies, and to communicate with our board of directors concerning our financial performance.


Free cash flows:
We define free cash flow as cash used in operating activities less purchases of property and equipment and capitalized internal-use software costs. We believe free cash flow is a useful indicator of liquidity that provides our management, board of directors, and investors with information about our future ability to generate or use cash to enhance the strength of our balance sheet and further invest in our business and pursue potential strategic initiatives.

Please see the reconciliation tables at the end of this release for the reconciliation of GAAP and non-GAAP results.

Forward-Looking Statements

This press release contains express and implied forward-looking statements including but not limited to, statements regarding our GAAP and non-GAAP guidance for the third fiscal quarter and full fiscal year 2022, the expected benefits and impact of the acquisition of Sensu, Inc. to Sumo Logic and its customers, and expectations regarding the benefits of our offerings, our growth strategy and investments, our market opportunity, and our ability to achieve success. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control. Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to our ability to realize the anticipated benefits from our acquisitions, our ability to successfully integrate the product offerings of Sensu with our own and to achieve customer acceptance of those offerings, our ability to achieve and maintain future profitability, our ability to attract new customers and retain and sell additional functionality and services to our existing customers, our ability to sustain and manage our growth, our ability to successfully add new features and functionality to our platform, our ability to compete effectively in an increasingly competitive market, and general market, political, economic, and business conditions, including the impact of COVID-19, and other risks detailed in our Quarterly Report on Form 10-Q for the fiscal quarter ended April 30, 2021, filed with the Securities and Exchange Commission (SEC) on June 4, 2021, and other filings and reports that we may file from time to time with the SEC. Additional information will be made available in our Quarterly Report on Form 10-Q for the quarter ended July 31, 2021 that will be filed with the SEC, which should be read in conjunction with this press release and the financial results included herein.

Past performance is not necessarily indicative of future results. The forward-looking statements included in this press release represent our views as of the date of this press release. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. We anticipate that subsequent events and developments could cause our views to change. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

About Sumo Logic

Sumo Logic, Inc. (Nasdaq: SUMO), is the pioneer in continuous intelligence, a new category of software, which enables organizations of all sizes to address the data challenges and opportunities presented by digital transformation, modern applications, and cloud computing. The Sumo Logic Continuous Intelligence Platform™ automates the collection, ingestion, and analysis of application, infrastructure, security, and IoT data to derive actionable insights within seconds. More than 2,100 customers around the world rely on Sumo Logic to build, run, and secure their modern applications and cloud infrastructures. Only Sumo Logic delivers its platform as a true, multi-tenant SaaS architecture, across multiple use-cases, enabling businesses to thrive in the Intelligence Economy. For more information, visit www.sumologic.com.

For more information, please contact:

Investor Relations Contact

Paul Thomas
[email protected]
(650) 214-3847

Media Contact

Melissa Liton
[email protected]
(650) 814-3882

Sumo Logic, Inc.

Condensed Consolidated Statements of Operations

(in thousands, except per share data)
(unaudited)

  Three Months Ended July 31,   Six Months Ended July 31,
  2021   2020   2021   2020
Revenue $ 58,841     $ 49,415     $ 113,060     $ 96,617  
Cost of revenue 19,778     14,113     35,173     28,539  
Gross profit 39,063     35,302     77,887     68,078  
Operating expenses:              
Research and development 23,861     15,304     44,304     33,003  
Sales and marketing 31,457     24,174     61,735     53,630  
General and administrative 16,670     7,512     31,243     16,589  
Total operating expenses 71,988     46,990     137,282     103,222  
Loss from operations (32,925 )   (11,688 )   (59,395 )   (35,144 )
Interest and other income (expense), net 69     (155 )   53     73  
Interest expense (3 )   (205 )   (89 )   (364 )
Loss before provision for income taxes (32,859 )   (12,048 )   (59,431 )   (35,435 )
Provision (benefit) for income taxes (810 )   169     (468 )   347  
Net loss $ (32,049 )   $ (12,217 )   $ (58,963 )   $ (35,782 )
               
Net loss per share, basic and diluted $ (0.30 )   $ (0.66 )   $ (0.56 )   $ (1.93 )
               
Weighted-average shares used to compute net loss per share, basic and diluted 107,884     18,649     105,990     18,522  



Sumo Logic, Inc.

Condensed Consolidated Balance Sheets

(in thousands)
(unaudited)

  July 31,

2021
  January 31,
2021
Assets      
Current assets:      
Cash and cash equivalents         $ 96,583     $ 404,140  
Marketable securities, current         192,652      
Accounts receivable, net         30,766     44,761  
Prepaid expenses         6,963     10,509  
Deferred sales commissions, current         14,163     12,790  
Other current assets         2,242     3,110  
Total current assets         343,369     475,310  
Marketable securities, noncurrent         82,454      
Property and equipment, net         5,098     4,156  
Operating lease right-of-use assets         8,210      
Goodwill         97,184     50,672  
Acquired intangible assets, net         35,030     10,656  
Deferred sales commissions, noncurrent         28,809     27,857  
Other assets         1,659     1,856  
Total assets         $ 601,813     $ 570,507  
Liabilities and stockholders’ equity      
Current liabilities:      
Accounts payable         $ 6,711     $ 4,832  
Accrued expenses and other current liabilities         20,284     23,316  
Operating lease liabilities, current         4,608      
Deferred revenue, current         108,035     102,625  
Total current liabilities         139,638     130,773  
Operating lease liabilities, noncurrent         4,666      
Deferred revenue, noncurrent         4,687     4,076  
Other liabilities         5,600     4,246  
Total liabilities         154,591     139,095  
Stockholders’ equity:      
Common stock         11     10  
Additional paid-in-capital         904,076     829,238  
Accumulated other comprehensive loss         (111 )   (45 )
Accumulated deficit         (456,754 )   (397,791 )
Total stockholders’ equity         447,222     431,412  
Total liabilities and stockholders’ equity         $ 601,813     $ 570,507  



Sumo Logic, Inc.

Condensed Consolidated Statement of Cash Flows

(in thousands)
(unaudited)

  Three Months Ended July 31,   Six Months Ended July 31,
  2021   2020   2021   2020
Cash flows from operating activities              
Net loss $ (32,049 )   $ (12,217 )   $ (58,963 )   $ (35,782 )
Adjustments to reconcile net loss to net cash used in operating activities:              
Depreciation and amortization 3,563     2,037     5,607     4,072  
Amortization of deferred sales commissions 3,764     2,730     7,165     5,214  
Accretion (amortization) of marketable securities purchased at a premium (discount) 801         1,367      
Stock-based compensation, net of amounts capitalized 14,057     4,656     26,190     9,723  
Non-cash operating lease cost 1,032         2,094      
Other (1,069 )   77     (1,046 )   82  
Changes in operating assets and liabilities              
Accounts receivable 13,880     (5,554 )   14,717     (2,461 )
Prepaid expenses 2,953     597     3,545     3,258  
Other assets 242     (70 )   1,386     180  
Deferred sales commissions (3,832 )   (3,980 )   (9,490 )   (6,918 )
Accounts payable 170     (2,089 )   1,553     (992 )
Accrued expenses and other current liabilities (2,773 )   2,023     (4,068 )   170  
Deferred revenue (4,291 )   (6,235 )   4,886     (6,133 )
Operating lease liabilities (1,113 )       (2,247 )    
Other noncurrent liabilities 127     1,242     47     1,681  
Net cash used in operating activities (4,538 )   (16,783 )   (7,257 )   (27,906 )
Cash flows from investing activities              
Purchases of marketable securities (24,122 )       (291,670 )    
Maturities of marketable securities 13,650         15,208      
Purchases of property and equipment (1,054 )   (175 )   (1,301 )   (190 )
Capitalized internal-use software costs     (488 )       (959 )
Cash paid for acquisitions, net of cash and restricted cash acquired (40,297 )       (40,297 )    
Net cash used in investing activities (51,823 )   (663 )   (318,060 )   (1,149 )
Cash flows from financing activities              
Proceeds from borrowings             24,250  
Payments of deferred offering costs     (262 )   (93 )   (556 )
Proceeds from employee stock purchase plan 4,725         4,725      
Proceeds from exercise of common stock options 5,308     1,252     13,327     2,123  
Cash paid for holdback consideration in connection with acquisitions     (100 )       (100 )
Net cash provided by financing activities 10,033     890     17,959     25,717  
Effect of exchange rate changes on cash and cash equivalents (140 )   233     (149 )   (58 )
Change in cash and cash equivalents and restricted cash (46,468 )   (16,323 )   (307,507 )   (3,396 )
Cash and cash equivalents and restricted cash:              
Beginning of period 143,401     114,740     404,440     101,813  
End of period $ 96,933     $ 98,417     $ 96,933     $ 98,417  



Sumo Logic, Inc.

Reconciliation of GAAP to Non-GAAP Financial Measures

(in thousands, except per share data and percentages)
(unaudited)

  Three Months Ended July 31,   Six Months Ended July 31,
  2021   2020   2021   2020
Reconciliation of gross profit and gross margin              
GAAP gross profit $ 39,063       $ 35,302       $ 77,887       $ 68,078    
Add: Stock-based compensation and related employer payroll tax 193       39       366       101    
Add: Amortization of acquired intangible assets 3,006       1,706       4,543       3,411    
Add: Acquisition-related expenses 54             54          
Non-GAAP gross profit $ 42,316       $ 37,047       $ 82,850       $ 71,590    
GAAP gross margin 66   %   71   %   69   %   70   %
Non-GAAP gross margin 72   %   75   %   73   %   74   %
               
Reconciliation of operating expenses              
GAAP research and development $ 23,861       $ 15,304       $ 44,304       $ 33,003    
Less: Stock-based compensation and related employer payroll tax (6,103 )     (1,849 )     (10,961 )     (3,878 )  
Less: Acquisition-related expenses (238 )           (238 )        
Non-GAAP research and development $ 17,520       $ 13,455       $ 33,105       $ 29,125    
               
GAAP sales and marketing $ 31,457       $ 24,174       $ 61,735       $ 53,630    
Less: Stock-based compensation and related employer payroll tax (4,291 )     (1,589 )     (8,013 )     (3,116 )  
Less: Amortization of acquired intangible assets (83 )           (83 )        
Less: Acquisition-related expenses (86 )           (86 )        
Non-GAAP sales and marketing $ 26,997       $ 22,585       $ 53,553       $ 50,514    
               
GAAP general and administrative $ 16,670       $ 7,512       $ 31,243       $ 16,589    
Less: Stock-based compensation and related employer payroll tax (3,906 )     (1,179 )     (8,094 )     (2,628 )  
Less: Acquisition-related expenses (2,540 )           (3,756 )        
Non-GAAP general and administrative $ 10,224       $ 6,333       $ 19,393       $ 13,961    
               
Reconciliation of operating loss and operating margin              
GAAP loss from operation $ (32,925 )     $ (11,688 )     $ (59,395 )     $ (35,144 )  
Add: Stock-based compensation and related employer payroll tax 14,493       4,656       27,434       9,723    
Add: Amortization of acquired intangible assets 3,089       1,706       4,626       3,411    
Add: Acquisition-related expenses 2,918             4,134          
Non-GAAP operating loss $ (12,425 )     $ (5,326 )     $ (23,201 )     $ (22,010 )  
GAAP operating margin (56 ) %   (24 ) %   (53 ) %   (36 ) %
Non-GAAP operating margin (21 ) %   (11 ) %   (21 ) %   (23 ) %
               
Reconciliation of net loss              
GAAP net loss $ (32,049 )     $ (12,217 )     $ (58,963 )     $ (35,782 )  
Add: Stock-based compensation and related employer payroll tax 14,493       4,656       27,434       9,723    
Add: Amortization of acquired intangible assets 3,089       1,706       4,626       3,411    
Add: Acquisition-related expenses 2,918             4,134          
Non-GAAP net loss $ (11,549 )     $ (5,855 )     $ (22,769 )     $ (22,648 )  
GAAP net loss per share $ (0.30 )     $ (0.66 )     $ (0.56 )     $ (1.93 )  
Non-GAAP net loss per share $ (0.11 )     $ (0.31 )     $ (0.21 )     $ (1.22 )  
Weighted average shares outstanding, basic and diluted 107,884       18,649       105,990       18,522    
               
Reconciliation of cash used in operating activities to free cash flow              
GAAP cash used in operating activities $ (4,538 )     $ (16,783 )     $ (7,257 )     $ (27,906 )  
Less: Capital expenditures (1,054 )     (175 )     (1,301 )     (190 )  
Less: Capitalized internal-use software costs       (488 )           (959 )  
Free cash flow $ (5,592 )     $ (17,446 )     $ (8,558 )     $ (29,055 )  



Cumulus Podcast Network’s Just Getting Started With Rich Eisen To Feature Special Fall 2021 Series “Voices Of Football”

First Episode, Featuring Al Michaels, is Now Live

PR Newswire

NEW YORK, Sept. 9, 2021 /PRNewswire/ — CUMULUS PODCAST NETWORK today introduces a special series for Fall 2021 called “Voices of Football” on the podcast, Just Getting Started with Rich Eisen.

The first episode in the series, now live, features Al Michaels in From Sun Devil to Sunday Night Football, discussing the full span of his career and decades calling football play by play.

Subsequent special episodes of Just Getting Startedwill drop each Wednesday and will be available at Apple Podcasts, Spotify, Stitcher, TuneIn, Pocket Casts, Google Podcasts, Amazon Music, and Pandora, among other platforms.

Now Live:

Al Michaels – From Sun Devil to Sunday Night Football

September 15:

Joe Buck – I’d Rather Be Working

September 22:

Erin Andrews – Thrown into the Deep End

September 29:

Kevin Harlan – A Life Full of Sports

October 7:

Jim Nantz – It’s Not a Big Deal

October 14:

Michael Strahan – To Be Announced

About Just Getting Started with Rich Eisen
Veteran sports broadcaster Rich Eisen is back with Season 2 of Just Getting Started. Rich sits down with the biggest voices in professional football. Al Michaels, Joe Buck, Erin Andrews and many others. Get a glimpse into their routines. Hear fresh stories about their lives and discover how they succeeded in their careers. New episodes will drop every Wednesday.

About Rich Eisen
In addition to Just Getting Started, Eisen also hosts The Rich Eisen Show for the CUMULUS Podcast Network as well as the pregame and halftime shows for CUMULUS MEDIA’s Westwood One Monday Night Football broadcasts. The Emmy-nominated broadcaster also hosts The Rich Eisen Show on Peacock TV, which airs weekdays from noon-3PM ET. This summer, Eisen hosted Tokyo Gold for Peacock TV, recapping the biggest stories and highlights from the Olympics. He continues to be the signature host of the NFL Network, where he was hired as the network’s first on-air talent in the summer of 2003. Prior to joining NFL Network, Eisen spent eight years at ESPN, where, as one of the network’s most visible personalities, he hosted SportsCenter alongside Stuart Scott, as well as a variety of other high-profile assignments. 

About CUMULUS MEDIA
CUMULUS MEDIA (NASDAQ: CMLS) is a leading media, advertising, and marketing services company delivering premium content to over a quarter billion people every month — wherever and whenever they want it. CUMULUS MEDIA engages listeners with high-quality local programming through 413 owned-and-operated radio stations across 86 markets; delivers nationally-syndicated sports, news, talk, and entertainment programming from iconic brands including the NFL, the NCAA, the Masters, CNN, the AP, the Academy of Country Music Awards, and many other world-class partners across nearly 7,300 affiliated stations through Westwood One, the largest audio network in America; and inspires listeners through the CUMULUS Podcast Network, its rapidly growing network of original podcasts that are smart, entertaining and thought-provoking. CUMULUS MEDIA provides advertisers with personal connections, local impact and national reach through broadcast and on-demand digital, mobile, social, and voice-activated platforms, as well as integrated digital marketing services, powerful influencers, full-service audio solutions, industry-leading research and insights, and live event experiences. CUMULUS MEDIA is the only audio media company to provide marketers with local and national advertising performance guarantees. For more information visit www.cumulusmedia.com.

Contact:

Karen Glover | CUMULUS MEDIA | [email protected] 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/cumulus-podcast-networks-just-getting-started-with-rich-eisen-to-feature-special-fall-2021-series-voices-of-football-301372952.html

SOURCE Cumulus Media

Janux Therapeutics Appoints Ron Barrett, Ph.D., and Alana McNulty to Board of Directors

Janux Therapeutics Appoints Ron Barrett, Ph.D., and Alana McNulty to Board of Directors

SAN DIEGO–(BUSINESS WIRE)–Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the additions of Ronald W. Barrett, Ph.D., and Alana McNulty as members of the Company’s Board of Directors. Dr. Barrett is a scientist entrepreneur with more than 30 years of experience in the biopharmaceutical industry, founding and leading biopharmaceutical companies, including advancing research that has led to FDA approval of three drugs. Ms. McNulty has more than 30 years of experience in finance and business development for private and publicly traded biopharmaceutical companies.

“Ron has deep expertise in building and operating biotech companies and successfully bringing a portfolio of preclinical drug candidates into clinical studies, including advancing a drug through FDA approval, and Alana has exceptional experience in finance and business development for a wide range of biopharmaceutical companies,” said David Campbell, Ph.D., President and CEO of Janux Therapeutics. “The Board and I welcome their complementary expertise as we continue to build the Company and look to advance our programs into the clinic.”

Dr. Barrett is CEO and Chairman of Medikine, Inc., a preclinical-stage biopharmaceutical company utilizing a proprietary platform to identify peptide mimetics of clinically relevant cytokines that interact with the broad class of heterodimeric cytokine receptors. Prior to Medikine he cofounded XenoPort, Inc., where he was the CEO and a Director for more than 15 years. Shortly after his tenure, XenoPort was acquired by Arbor Pharmaceuticals, LLC. Under his guidance, XenoPort completed multiple private and public financings, corporate partnerships, and advanced five in-house discovered compounds into human trials including mid- to late-stage clinical trials. He led the company’s efforts that resulted in the FDA approval of HORIZANT® (gabapentin enacarbil), the first and only non-dopaminergic drug approved for moderate to severe restless legs syndrome in the U.S. Prior to founding XenoPort, Dr. Barrett was Senior Vice President of Research at Affymax Research Institute, where he pioneered the development and use of new drug discovery technology – work that led to two FDA-approved medicines. He is currently a Director of Concert Pharmaceuticals, Inc. and Quadriga Bioscience, Inc. Dr. Barrett co-authored more than 50 manuscripts in peer-reviewed journals and is an inventor on more than 50 issued patents in the U.S. He received a B.S. degree in biology from Bucknell University and a Ph.D. degree in pharmacology from Rutgers University.

Over her career, Ms. McNulty has led or played a key role in transactions with an aggregate value greater than $2 billion, including private and public financings, mergers and acquisitions, corporate partnerships, and debt financings. She is currently Chief Business Officer of eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs known as selective translation regulator inhibitors (STRIs). She also served as Chief Financial Officer for eFFECTOR for more than eight years. Prior to eFFECTOR, Ms. McNulty served as Chief Financial Officer of a number of biopharmaceutical companies, including Lumena Pharmaceuticals, Inc. (acquired by Shire plc), Excaliard Pharmaceuticals, Inc. (acquired by Pfizer Inc.), BrainCells Inc., and Elitra Pharmaceuticals, Inc. Prior to that, Ms. McNulty was Head of Corporate Development and a General Manager of a business unit at Advanced Tissue Sciences, Inc. Ms. McNulty received a B.A. in biology with high honors from UC Santa Barbara, where she graduated Phi Beta Kappa, and an MBA from the Anderson School of Business at UCLA.

About Janux Therapeutics

Janux Therapeutics is an innovative biopharmaceutical company developing next-generation therapeutics based on applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms to better treat patients suffering from cancer. Janux’s initial focus is on developing a novel class of T cell engagers (TCEs), and its lead product candidates are designed to target clinically validated drug targets. While TCE therapeutics have displayed potent anti-tumor activity in hematological cancers, developing TCEs to treat solid tumors have faced challenges due to the limitations of prior TCE technologies, namely (i) overactivation of the immune system leading to cytokine release syndrome, (ii) on-target, healthy tissue toxicities, and (iii) poor pharmacokinetics leading to short half-life. Janux is using its TRACTr platform technology to engineer product candidates designed to overcome these limitations. Janux is developing a broad pipeline with lead TRACTr programs targeting prostate-specific membrane antigen (PSMA), epidermal growth factor receptor (EGFR), and trophoblast cell surface antigen 2 (TROP2), and its lead TRACIr program targeting PD-L1xCD28, with all of its programs currently in the IND-enabling or discovery stage. For more information, please visit www.januxrx.com.

Forward-Looking Statements

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, Janux’s ability to bring new treatments to cancer patients in need, and the progress and expected timing of Janux’s drug development programs. Factors that may cause actual results to differ materially include the risk that compounds that appear promising in early research do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Janux may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings and applications, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Janux faces, please refer to Janux’s periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Janux assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Media:

Jessica Yingling, Ph.D.

Little Dog Communications Inc.

[email protected]

(858) 344-8091

Investors:

Christina Tartaglia

Stern Investor Relations, Inc.

[email protected]

(212) 362-1200

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Oncology

MEDIA:

Logo
Logo

Hims & Hers Health to Present at Upcoming Financial Conferences

Hims & Hers Health to Present at Upcoming Financial Conferences

SAN FRANCISCO–(BUSINESS WIRE)–
Hims & Hers Health, Inc. (“Hims & Hers”, NYSE:HIMS), the multi-specialty telehealth platform focused on providing modern personalized health and wellness experiences to consumers, announced today that its management team will participate at two upcoming conferences:

  • Citi’s 2021 Virtual Global Technology Conference, taking place Monday, September 13th – Wednesday, September 15th with one-on-one investor meetings throughout the day on September 14th.
  • Raymond James Consumer Conference on Tuesday, September 14th, 2021. A fireside chat presentation with Chief Executive Officer Andrew Dudum will be webcast live at 4:20pm ET and will be available on Hims & Hers investor relations website at https://investors.forhims.com/. The webcast will be archived and available for 90 days.

For more information about the conferences, or to schedule a one-on-one meeting with Hims & Hers management, please contact your appropriate representative directly, or email Hims & Hers investor relations at [email protected].

About Hims & Hers Health, Inc.

Hims & Hers is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to primary care, mental health, sexual health, dermatology, and more. Launched in November 2017, the company also offers thoughtfully created and curated health and wellness products. With products and services available across all 50 states and Washington, D.C., Hims & Hers is able to provide access to quality, convenient and affordable care for all Americans. Hims & Hers was founded by CEO Andrew Dudum, Hilary Coles, Jack Abraham and Joe Spector at venture studio Atomic in San Francisco, California. For more information about Hims & Hers, please visit forhims.com and forhers.com.

Investors:

Bishop IR

Mike Bishop

(415) 894-9633

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Technology Health General Health Pharmaceutical Mental Health Cosmetics Telecommunications Retail VoIP Fitness & Nutrition Mobile/Wireless

MEDIA: